This report was first published by Endpoints News. To see the original version, click here
Jiangsu Hengrui Pharmaceuticals has quietly become a top 25 biopharma company in the world by market value.
Once virtually unknown outside of China, the company has made its name overseas via an R&D engine that has not only spawned over 20 approved drugs in China, but also new startups — including a billion-dollar obesity biotech — and expansive deals with Western drugmakers.
您已阅读6%（467字），剩余94%（7904字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。